Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Soaring cannabis stock primed and ready for a take-out

Investors were put on bid alert after it emerged the company had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.
Soaring cannabis stock primed and ready for a take-out
The interest comes as the company as it prepares to bring to market Epidiolex, a cannabis-derived medication to treat a severe form of childhood epilepsy.

Shares in GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH) were up almost 20% in afternoon trade amid reports the company has multiple potential suitors.

Investors were put on bid alert after it emerged the company had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.

The interest comes as the company as it prepares to bring to market Epidiolex, a cannabis-derived medication to treat a severe form of childhood epilepsy.

Analysts say the drug has the potential to deliver annual sales of around US$800mln.

According to Reuters, the financial news agency that broke the story, the identities of the potential GW Pharma suitors are unknown.

However it points out the big beasts in this sphere of the drugs market are Novartis (ETX:NOVN), Bayer (ETR:BAYN) and Almirall (BME:ALM).

However London broker Numis reckons Lundbeck (CPH:LUN), Otsuka (TYO:4578) and Biogen (NASDAQ:BIIB) might also be in the running.

Analyst  Paul Cuddon said: “With phase-three data on Epidiolex  (the key attraction)…due in the coming weeks and more data expected in December the timing is intriguing, allowing a potential acquirer an effective first option on the data.”

However he cautioned there are still “significant clinical, regulatory and commercial risks” associated with the treatment.

The shares, which are LSE and Nasdaq-quoted, were up 105p at 631.5p in a busy transatlantic trading session. That values the business at just shy of £2bn.

In the past six months the stock has advanced 178%, buoyed by some encouraging headline results from a phase III clinical trial of Epidiolex.

On the back of that the company was able to raise £190mln from US investors to bankroll the further development of its lead product.

Ian_55ae0ddd437b7.jpg


Register here to be notified of future GWP Company articles
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

Blood testing
February 13 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.
Bankroll.jpg
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
Concept of a DNA strand
May 30 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use